Gtp Cyclohydrolase I Deficiency C0268467
A metabolic disorder affecting the body's ability to produce a key enzyme for processing certain amino acids. Treatment involves dietary modifications and supplementation under specialist care.
Key facts at a glance
- ICD-10
- E88.9
- ICD-11
- 5A00.0
- Body system
- metabolic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Seizures
Fatigue or weight changes
(metabolic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Hyperphenylalaninemia
(metabolic)Dystonia
(neurological)Developmental delay
(neurological)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Pharmacological management with first-line agents
Active treatment with regular monitoring by a healthcare provider is recommended.
Tetrahydrobiopterin (BH4) supplementation
BH4 replacement therapy addresses the underlying enzymatic deficiency in GTP cyclohydrolase I deficiency. This dopamine precursor therapy supports neurotransmitter synthesis and may improve motor and non-motor symptoms.
Neurotransmitter and biochemical monitoring
Regular monitoring of neurotransmitter metabolites in CSF and clinical assessment guides treatment optimization. Biochemical markers help assess response to BH4 supplementation and inform dose adjustments.
Additional treatment options
Dopamine agonist therapy
Dopamine agonists such as pramipexole or ropinirole may supplement BH4 therapy to address dopaminergic deficiency. These agents help manage motor symptoms including rigidity, bradykinesia, and tremor.
medicationPhysical activity and exercise programming
Regular exercise program tailored to individual motor capabilities supports functional mobility and may enhance dopaminergic function. Balance training and gait optimization reduce fall risk.
lifestyleAmino acid supplementation and dietary optimization
Dietary management including supplementation of amino acid precursors that support neurotransmitter synthesis. Protein timing and distribution throughout the day may optimize medication effectiveness.
dietaryWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Gtp Cyclohydrolase I Deficiency C0268467?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Gtp Cyclohydrolase I Deficiency C0268467. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy